Details of the Drug Combinations

General Information of This Drug (ID: DM7J6OR)

Drug Name

Tocilizumab DM7J6OR

Synonyms

Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody

Indication

Disease Entry	ICD 11	Status	REF
Giant cell arteritis	4A44.2	Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Juvenile idiopathic arthritis	FA24	Phase 3	[2]
Castleman's disease	4B2Y	Investigative	[4]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tocilizumab + Azithromycin	DCV09V7	Azithromycin	Coronavirus Disease 2019 (COVID-19)	[5]
Tocilizumab + Azithromycin	DCXKIA6	Azithromycin	Coronavirus Disease 2019 (COVID-19)	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6881).
3	ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
4	Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.
5	ClinicalTrials.gov (NCT04347031) An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. U.S. National Institutes of Health.